

The Finnish hockey club KalPa extends its agreement PolarCap® agreement for another three years

Finnish ice hockey league (Liiga) team KalPa has extended its agreement for the PolarCap® System until 2027. KalPa has used PolarCap® over the past two seasons for the treatment of players suffering from concussions, with positive experience.

PolarCool develops and markets the product PolarCap®, which alleviates the effects of concussions. The primary users of PolarCap® include sports clubs, organizations, and facilities in contact sports such as ice hockey, rugby, football, and handball, but also other sports with an increased risk of concussion.

Finnish top club KalPa are one of several clubs that have chosen to extend their current contracts with PolarCool. It was also recently announced that the Swedish champions Skellefteå AIK extended their agreement until 2027. In 2022 KalPa was the first club in Finland to implement treatment with PolarCap® in its concussion routines.

The club's positive experiences, alongside the compelling results from the published 5-year PolarCap® study, clearly demonstrate the value of continued PolarCap® use and form the basis for KalPa's decision to extend the agreement.

KalPa's CEO Toni Saksman comments:

- *I am very pleased with the opportunity we have to be able to treat our players with PolarCap® in the acute phase if they suffer a concussion. For KalPa, the safety and well-being of our players is a priority and actively showing that we take care of our players in the best possible way is something we value. A healthy player is crucial for us as a club and team, but above all for the players themselves.*

PolarCool CEO Erik Andersson comments:

- *KalPa is another example of customer satisfaction for the PolarCap® System. We now see an increasing number of customers entering a second or third contract period. It is a receipt for the value we create for our customers. Our ambition is for the establishment to gain further momentum in Liiga as we notice that many clubs are awaiting a response from the clubs that were the first to implement PolarCap®.*

The agreement with KalPa is strategically important, even if the financial significance of individual agreements is limited.

For more information

Erik Andersson – CEO

+46 – 73 860 57 00

E-mail: erik.andersson@polarcool.se

About PolarCool AB (publ.)

PolarCool AB (publ.) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ.) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.